Neonmind’s NEO-002 artificial psilocybin applicant might be researched as a minimal-dose treatment to regulate and suppress patient hunger. The company has secured pharmaceutical grade synthetic psilocybin from Psygen and anticipates initiating a Stage I/II evidence-of-concept analyze for NEO-001 during the in close proximity to long term. While Heading focuses https://solangeb086ajr5.blogdosaga.com/profile